Ark Animal Health

Ark Animal Health is a wholly owned subsidiary of Sorrento. Ark was formed in 2014 to bring to the companion animal market innovative solutions issued from Sorrento’s human research and development activities. It is being organized to become a fully independent and self-sufficient organization once it reaches commercial stage (products ready to receive FDA approval).

Ark’s lead development program (ARK-001) is a single dose resiniferatoxin (RTX) sterile injectable solution. ARK-001 has received FDA CVM (Center for Veterinary Medicine) MUMS (minor use/minor species) designation for the control of bone cancer pain in dogs. Other projects include additional indications for RTX in areas such as chronic articular pain in companion animals, neuropathic pain in horses, and idiopathic cystitis in cats, as well as exploring development opportunities in the area of infectious diseases or cancer treatment.